Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials

INTRODUCTION: Differences in psoriatic arthritis (PsA) treatment response between sexes for ixekizumab, an interleukin-17A antagonist, are largely unexplored. This analysis used data from randomized clinical trials (RCTs) evaluating ixekizumab to study differences in treatment response between male...

Descripción completa

Detalles Bibliográficos
Autores principales: Eder, Lihi, Tony, Hans-Peter, Odhav, Satish, Agirregoikoa, Eva Galindez, Korkosz, Mariusz, Schwartzman, Sergio, Sprabery, Aubrey Trevelin, Gellett, Amanda M., Park, So Young, Bertram, Clinton C., Ogdie, Alexis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127019/
https://www.ncbi.nlm.nih.gov/pubmed/35397092
http://dx.doi.org/10.1007/s40744-022-00445-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127019/
https://www.ncbi.nlm.nih.gov/pubmed/35397092
http://dx.doi.org/10.1007/s40744-022-00445-w

Ejemplares similares